Helsinn sets up a boutique investment fund with a roving eye for oncology upstarts
If you’re starting up an early-stage biotech focused on cancer R&D, Helsinn has set up a boutique venture arm that just might be interested in stepping in at the ground floor.
Until now, the Swiss company has been focusing its attention on cancer supportive care, primarily backing late-stage work. But the new Helsinn Investment Fund is designed to join syndicates with an eye for early stage plays.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.